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S312 Poster Session Iactivities. More than 2/3 of PHO providers stated that they pro-
vide BMT services at their institutions, most commonly inpatient
coverage (73%). The proportion of providers exposed to BMT
early in their training was significantly higher amongst BMT pro-
viders than PHO providers (51% vs. 18% during medical school
[p\0.0001] and 70% vs. 50% during residency [p\ 0.005]). Ex-
posure during fellowship (94%) did not differ amongst groups.
The decision to pursue a career in BMT was made before fellow-
ship (medical school or residency) in 50% of the respondents. A
lower proportion of BMT providers reported currently being in-
volved in education of medical students and residents compared
to PHO providers (98% vs. 76%, p\0.0001). Of 53 trainees,
64% reported that they were not contemplating a career in
BMT. Of these, 68% stated that inadequate exposure to BMT
prior to PHO fellowship was the reason. Only 26% reported
BMT exposure in medical school and 43% during residency.
The two most common reasons for the choice of a BMT career
were the degree of intellectual and scientific challenge (89%)
and role models/mentors in the field (67%). This survey suggests
that early exposure to BMT during medical school and residency
results in increased interest in pursuing a career in BMT. BMT
physicians and training program directors can foster interest in
the BMT field by promoting BMT focused education and clinical
inpatient and outpatient rotations during medical school and res-
idency. This early exposure to BMT may aid in a higher recruit-
ment of future transplant providers.289
HIGH DOSE METHYLPREDNISOLONE FOR VENO-OCCLUSIVE DISEASE OF
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Mehta, P.A.1, Davies, S.M.1, Jodele, S.1 1Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH; 2Cincinnati Children’s HospitalMedical
Center, Cincinnati, OH
Veno-occlusive disease (VOD) of the liver is a well-recognized se-
rious complication of stem cell transplantation (SCT) with very few
successful treatment modalities available for severe disease. While
there have been some reports demonstrating success in adults with
high dose steroid therapy, experience in the pediatric population is
lacking. In 587 consecutive SCT patients treated at our institution
since 2003 we retrospectively identified 14 (2.4%) who developed
VOD.Of these 8 (57%) were treated with high-doseMethylprednis-
olone (500 mg/m2/dose every 12 hours for 6 doses). Steroid therapy
was initiated at or prior to first ultrasound evidence of reversal of
portal venous flow, and prior to meeting criteria for initiation of de-
fibrotide therapy. Four of these patients were also treated with De-
fibrotide starting 2 to 5 days following initiation of steroids. Seven
patients with VOD were diagnosed with multi-organ failure
(MOF) due to renal impairment and pulmonary dysfunction attrib-
utable to fluid overload or mechanical impingement from abdominal
distention or hepatic enlargement. Four of these 7 patients required
renal replacement therapy (RRT) and 5 required ventilator support
(see Table). Response to high dose steroid therapy as defined by de-
crease in bilirubin by 50% by ten days from therapy initiation wasTable.
Patient / Dgn Donor (match) Age (years) Portal System Doppler Days
1 / PPB Auto 7 Reversal of Flow
2 / CGD URD (7/8) 10.6 Reversal of Flow
3 / RB Auto 0.7 Reversal of Flow
4 / ALL MSD (8/8) 16.2 Reversal of Flow
5 / FA MUD (8/8) 6.3 Reversal of Flow
6 / NB Auto 6.6 Reversal of Flow
7 / ALL MUD (8/8) 4.8 Reversal of Flow
8 / DKC MSD (8/8) 1.2 Reversal of Flow
BMT indicates bone marrow transplant; DKC, dyskeratosis congenita; MSD, m
tologous stem cell transplant; ALL, acute lymphoblastic leukemia; MUD, matche
ulomatous disease; URD, unrelated donor; **RRTand ventilator support, *vennoted in 5/8 (63%) patients, occurring within 3 and 6 days of steroid
therapy. Two patients died due to VODwithMOF. Six survivors re-
covered from VOD at the median 15d (range 4-40) from VOD diag-
nosis. Overall survival as a groupwas 75%; however survival amongst
responders was 100%. No serious toxicities related to high dose ste-
roid therapy, such as refractory hypertension, increased infection, or
behavioral disturbances were observed. Transient hyperglycemia
was seen in some patients. We conclude that high dose steroid ther-
apy if initiated early may reverse VOD of the liver in pediatric SCT
patients, abrogating the need for defibrotide therapy with its associ-
ated toxicities and regulatory difficulties. Further prospective clinical
trials are required to assess the true efficacy of high dose steroid ther-
apy for post SCT VOD.290
BONE HEALTH IN CHILDREN AND ADOLESCENTS UNDERGOING HEMA-
TOPOIETIC CELL TRANSPLANTATION IN A SINGAPORE CENTER
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Chua, H.C.1, Villegas, M.S.1, Lee, Y.S.1, Tan, P.L.1 1National Univer-
sity Health System, Singapore; 2National University Health System, Sin-
gapore; 3Yong Loo Lin School of Medicine, National University of
Singapore, Singapore
We retrospectively reviewed 103 pediatric patients transplanted
between 2001-2010 to evaluate the prevalence of low bone mineral
density (BMD). Areal BMD of the lumbar spine and whole body
were determined by dual energy X-ray absorptiometry (DXA) im-
aging. Z-scores calculated were standardized by age and gender
based on a reference population. BMD was defined as normal if
Z-score . -1.0; borderline low if -2.0 \ Z-score # -1.0; low if
Z-score # -2.0; and osteoporosis if Z-score # -2.0 with a history
of fracture. Spine Z-scores were used in analysis. Only 45 of the
103 patients had any BMD records. Of these, 18 had serial
BMD evaluations. The median age at time of hematopoietic cell
transplant (HCT) was 10.2 (range, 0.1-16.8) years. Forty-three pa-
tients had allogeneic (4 had 2 HCT) while 2 had autologous HCT.
Majority (N 5 30) received non-radiation based preparative regi-
men; the commonest indication being a hematologic malignancy
(N 5 33). Majority (N 5 33) had graft versus host disease; 27 of
whom required systemic steroids. Of the patients who had pre
HCT BMD, 45% (5 of 11) already had abnormal Z-scores. Trend-
ing of BMD was possible in 17 of the 45 patients who had more
than one BMD. Recovery from a nadir Z-score was noted in
40% (7 of 17) of these patients at the time of analysis. Of the pa-
tients who had post HCT BMD, 23% (9 of 39) and 28% (11 of 39)
had borderline low and low Z-scores, respectively. One of these 20
patients (5%) had clinically significant fractures fulfilling the
WHO criteria for osteoporosis. Musculoskeletal pains were re-
ported by 29% (13 of 45) of patients but an abnormal Z-score
was noted in only 60% (8 of 13). Endocrinopathies including sex
hormones and thyroid function deficiencies was noted in 13% (6
of 45) of patients. The 3 patients with hypogonadism also had ab-
normal BMD and required hormonal replacement. One of these 3
patients received an oral bisphosphonates. Majority had calcium/
vitamin D supplements and about half (19 of 45) had physiother-
apy to optimize bone health. Despite the limitations known offrom BMT to VOD Therapy Multiorgan Failure Status
+31 Steroids Yes Alive
+11 Steroids No Alive
+14 Steroids Yes* Alive
+16 Steroids/Defibrotide Yes** Alive
+15 Steroids/Defibrotide Yes** Dead
+13 Steroids/Defibrotide Yes** Alive
+12 Steroids Yes Alive
+5 Steroids/Defibrotide Yes** Dead
atched sibling donor; NB, neuroblastoma; RB, retinoblastoma; Auto, au-
d unrelated donor; PPB, pleuropulmonary blastoma; CGD, chronic gran-
tilator support.
Poster Session I S313BMD as a surrogate marker of bone health in children/ adoles-
cents, the prevalence of compromised bone health determined by
DXA correlated with symptoms in our cohort demonstrated the
value of this objective measure. There is need to systematize
BMD evaluations to optimize the opportunities of restoring
bone mineral loss during the growing years of pediatric HCT
recipients.
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FUTURE RESEARCH NEEDS FOR HEMATOPOIETIC STEM-CELL TRANS-
PLANT IN PEDIATRICS
Belinson, S.E., Mauger Rothenberg, B., Chopra, R., Aronson, N. Blue
Cross Blue Shield Association, Chicago, IL
Objectives:To systematically prioritize research gaps in the areas of
HSCT for pediatric malignant solid tumors, inheritedmetabolic dis-
ease, and autoimmune disease. In addition to develop a list of re-
search questions to address the prioritized gaps identified in
a comparative effectiveness review of HSCT for pediatrics.
Methods: Central to the methodology of this report was the use of
key informants to identify and prioritize evidence gaps. We elicited
expert opinion from a group of nine clinical experts, to ensure clin-
ical relevance, a group of patient advocates, and a payer. Through an
iterative process, the key informants identified and prioritized re-
search gaps. They then generated and prioritized a list of potential
research studies to address these gaps. For the assessment of study
designs, we evaluated the appropriateness of a randomized trial,
a nonrandomized trial, and a cohort design.
Results: Seven research gaps were identified through a combina-
tion of the HSCT CER and conversations with key informants.
The patient advocates provided a valuable, unique perspective
that resulted in the identification of two additional research gaps
and associated research questions. With the patient advocates we
intended solely to focus on discussing outcomes. However, the ad-
vocates broadened the discussion which in the end coalesced
around issues central to the concept of a patient-centered medical
home, which could provide the long-term clinical and pharmacy
support to help a family from diagnosis to the transition from
the treatment center back to their community and then through
long-term follow-up. The final prioritized list of gaps is cross-cut-
ting in that each gap applies to more than one indication for
HSCT. These appear with their associated key questions, in order
of priority in Table 1.
Conclusions: In addition to the prioritized gaps and key questions
highlighted by this work, the role of patient advocates, in this case
mothers of transplant recipients, was essential to the identification
of research gaps along the entire continuum of care from diagnosis
to long-term follow-up.Table 1. RESULTS: Prioritized gaps and key questions
Prioritized Gap
1. Mitigation of long term adverse effects by changes in regimen, including
reduced intensity approaches, and changes in subsequent medical or
psychosocial intervention.
2. Role of novel therapies for HSCT in altering short-term adverse effects
and the long-term effects of these therapies. Such approaches include:
3. Impact on outcomes of a ‘‘family-centered’’ approach to transplantation.
Advocates of children who have undergone HSCT defined such an
approach as including: emotional and psychosocial counseling for the
family with a special attention on donor and non-donor siblings,
information to share with caregivers and peers, and, provision of tools
rather than only a large amount of information for navigating the
complexities of the medical system and medication management.
4. Effectiveness of survivorship planning on long term, comprehensive
follow-up and outcomes.292
SAFETY ANALYSIS OF UPPER GASTROINTESTINAL TRACT ENDOSCOPY IN
CHILDREN AND ADOLESCENTS AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION: A FIVE-YEAR, SINGLE-INSTITUTION
SURVEY
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versity Children’s Hospital Muenster, Muenster, Northrhine Westfalia,
Germany; 2University Children’s Hospital Muenster, Muenster, North-
rhine Westfalia, Germany
Indroduction:Upper gastrointestinal tract (GIT) endoscopy is a fre-
quent procedure after allogeneic HSCT, mainly in the context of
suspected GvHD.Here, we report our analysis of upper GIT endos-
copy in a pediatric, allogeneic HSCT cohort over a period of five
years with a special focus on safety aspects.
Patients and Results: From 2007 to 2011, 24 of 86 (28%) pediatric
allogeneic HSCT patients had upper GIT endoscopy for various
reasons between days +2 and +1079 with a median of day +72. The
total number of procedures was 57 with 14 patients having multiple
procedures (2-7). The 15 males and 9 females were between 2 to 22
years old (mean 10.2, median 9 years) at the time of their first proce-
dure. Their diagnoses were ALL (11), Fanconi anemia (5), MDS (3),
AML (3), Dyskeratosis congenita (1) and Shwachman-Diamond syn-
drome (1). Transplants were from MSD in 5, from MUD and
MMUD in 15 and 4 patients, respectively. The mean platelet count
before the procedure was 148000/ml (26000-347000), mean PT
100% (55-130), mean PTT 30sec (23-42) and mean fibrinogen
384mg/dl (113-758). The procedures were primarily performed by
pediatric gastroenterology or pediatric surgery and only rarely by
adult gastroenterology. The safety analysis included the need of pro-
cedure-related initiation or prolongation of mechanical ventilation,
blood pressure support, need of transfer to the ICU, GIT wall per-
foration, occurrence of GIT hemorrhage, and any clinically relevant
disturbance of GIT motility. Altogether, procedural adverse events
were noted in 1 of 57 procedures (1.8%): A 3-year-old girl had to
be transferred to the pediatric ICU on the day of her procedure
for life-threatening intestinal hemorrhage at the site of a duodenal
biopsy. One day later she also developed a complete duodenal ob-
struction caused by an intramural duodenal hematoma. Platelet
count and coagulation parameters were not different from other pa-
tients in this analysis. Over a period of 4 weeks, the obstruction re-
solved. Possible risk factors in this patient were treatment with
defibrotide and disseminated adenovirus disease. All other patients
in our analysis had an unremarkable post-procedural course.
Conclusions: Despite of the existence of several potential risk fac-
tors, upper GIT endoscopy in children and adolescents after alloge-
neic HSCT usually is a safe procedure. Intestinal hemorrhage and
duodenal wall hematoma with mechanical obstruction is an infre-
quent, but potentially life-threatening adverse event.Key Questions
1.1 Can intense psychological support of patient, parents and siblings prevent
development of post-transplant psychological disorders (including PTSD,
depression, anxiety, other adverse psychological outcomes) in ‘‘surviving’’
and ‘‘non-surviving’’ family members?
2.1 For pediatric patients receiving a transplant due to cancer: Are there
interventions that maymitigate immediate and late adverse effects without
interfering with the immunotherapeutic effects? 2.2 For pediatric patients
receiving a transplant for non-cancerous indications: Are there
interventions that maymitigate immediate and late adverse effects without
interfering with the establishment and maintenance of chimerism?
3.1 What approached to integrated care, from diagnosis forward, have the
greatest impact in family functioning and overall health and well-being for
families faced with pediatric transplant?
4.1 Does survivorship planning enhance compliance with long-term follow-
up? 4.2What are the comparative outcomes for those that participate in
long-term survivorship follow-up versus those who do not?
